Member Info for Doc.Daneeka

Covid deaths will be with us until cases drop to nothing. It's been a long time since the last boosters and immunity is waning. Overwhelmingly the deaths are in the over 75s but that doesn't make it any less concerning. And as we discussed yesterday only a fraction of the 9m eligible for Evusheld have actually received it. Let's hope the new boosters do their job

I said Polygon "came here for Covid " Fruits. You're the one who said "only here for Covid"
Someone else will probably know when they first invested - and I could be completely wrong - but either way I didn't say what your deliberate misquote suggests.

realism
noun
the attitude or practice of accepting a situation as it is and being prepared to deal with it accordingly.

I came here for Covid. Along with thousands of other large and small investors including Polygon. If we've missed that boat - and I don't think we have yet, but I do think that Strive is our main and possibly only chance of getting on the trial we need - then it's unquestionably a terrible failure.
If we end up on a flu or COPD or asthma trial then that will also be positive - but it'll take a lot longer as we have just a partially completed P2 for COPD and nothing for the other two.
If somehow Synairgen has managed to miss the opportunity of a lifetime to prove its drug (where was the company going before Covid) then it'll be tremendously sad. Sad for us as investors -but mostly sad for the thousands of lives that might have been saved. If the Covid trials still manage to propel the drug and company forward and eventually we see SNG in hospitals for one or all of these respiratory conditions then everything will have been worth it. We'll never get the profits we might have done if they'd not muffed Sprinter so badly but at least there's achance we might see SNG finally helping people and saving lives.
I'll reserve judgement on the whole thing until we hear about Sprinter

ah... and 2 minutes later here she is. Morning Mani , hope you're well. Really proud of that Cormac McCarthy line - so thanks for reposting

Gunto the combination trials suggestion was made by Stacey in her Grand Rounds presentation but i'm pretty sure it was in the outpatient setting. And i think Monoclonals have been proven in so many trials to not work in the hospital setting that I don't think they'll be a threat. Immunomodulator guidance is discussed here. Clearly Fluvoxamine thinks it still has a chance but NIH is not keen.
https://www.covid19treatmentguidelines.nih.gov/therapies/immunomodulators/summary-recommendations/

You really are a nasty pice of work Td. Nothing in my recent posts is negative or attempts to create some nefarious agenda. You're so stuff full of ramp that you fought bitterly against my very reasonable and completely supported post suggesting we'd most likely be looking at 1000+ plus for the next trial - and here's RM saying exactly the same thing. You keep on with your cut and paste exercise and leave those of us who you disagree with in peace. I told you before that my posts are not for you and that still holds.
My post about Synairgen's changed language was equally accurate but it didn't suit your agenda so you misrepresent it again and again. Push off.

Starting a new thread for this to consider the questions raised by Size82. Not offering anything else up as such, more to underline a couple of points that should make SNG the strongest candidate - and hope others can fill in with details of other competing therapies.
The main point that supports our hope for inclusion - and perhaps even to be the first candidate - is the Sprinter post-hoc analysis that showed such a strong signal in the most at risk patients in hospital - even on top of SOC. I don't need to re-present it here but by all measures it was impressive. It needs to be peer reviewed for sure - but if NIH is considering SNG it has the scientists to do that job ahead of any published pr.
Why do these stats make us a strong candidate ? Because nothing else has been trialed successfully to this level in hospitals yet. Nothing. In the whole world. It's a little nugget that can hopefully be proven and expanded on with the right trial design and holds the possibly of saving another 1/3 of lives in hospitals.
And it can be given on admission to the most at risk population - those we know are most likely to end up in ICU. Given well before Dexamethasone can be safely administered.
What else is coming along ? Hopefully others can answer ?
Dexa higher dose is still trialling on Recovery - as are Mol and Paxlo. All of the A3 Mabs failed in hospitals. Outpatient setting will alost certainly see new authorisations in the near future, but that's shifting sand and as new ones are approved old ones may be deleted (although protease inhibitors are retaining multi-viral function when Mabs do not )
Still hopeful Gilead might be there somewhere - as per that intriguing paragraph i posted yesterday. Remdes has co-trialled with almost everything in hospitals and it would be a great partner / future owner.
The other question Size raises is "what are the factors which could mean SNG is overlooked " And that answer is - I'm afraid - down to the size and influence of the company. Would we have completed a successful P3 with a BP partner - we all believe so. Are the power brokers in NIH and NIHR overly influenced by Big Pharma - undoubtedly so. But science is above all else a numbers game, and whatever our disadvantages we do appear to have the numbers.

Not answering for Ghia Size82 - but clearly if we miss this last winter of Covid to trial SNG we might as well all go back to cutting sods, and our brightest scientists might as well run naked from HQ and throw themselves into the Solent. Everything is primed and ready for the one PT that will get us over the line before SNG enters its own long winter. And unless we get the joojoo juice back in the building that only something like Strive can generate - the whole project dessicates and shrivels until anyone considering a JV for anything will just buy the company for whatever they have in their pocket. Discovered but unauthorised drugs are like diamonds stolen from a poor man's dirt and set into someone else's crown.
Listening to RM in that presentation he didn't sound like a man on the brink of greatness. He even included "private researchers" in the people Syn might want to buddy up with to get any kind of trial going. He's either got the best poker voice in history or he's still scratching around for something. And if he is still scratching around that means NIH have not given him the nod. And if they don't give him the nod - and we start hoping we'll get onto the not even launched UK flu trial - then the £85 mill has just gone and the future is a short story written by Cormac McCarthy .

That's what we're trying to do consigliere - but there's this yapping mutt that keeps interrupting

permanent caps are generally accepted as a sign of madness in any social media context. try to find your inner eecummings mani

As if..... Eva was A LOT MORE FUN !! (and brighter)

Ghia please don't respond to Mani. She fights Tommy's fights - butts in when nobody asked her and has never ever contributed anything of value to the discussion on this board beyond constant list making of all the upsides.
Let her scream at the moon and bang her little tambourine and if you've asked a reasobnable question wait for others with more perspective to engage in the debate.

I nearly posted recently that a joint trial with remdes would have been worthwhile , but of course it's SOC so I guess you get it anyway. Dream scenario would be to somehow replace Dexa for all hospitalised patients except ICU.

https://www.biospace.com/article/uk-s-synairgen-reports-positive-covid-19-treatment/

July 20th 2020 - when the world was young.....

Looking back at the how the world greeted the SG016 success ( to cheer myself up ) and came across this intriguing paragraph from Biospace. Written the day itself - July 20th 2020 and sounded like based on interview/briefings

"In addition to waiting for peer review of this data, the company is planning further studies, including with Gilead Sciences’ remdesivir, the only treatment approved for use for COVID-19 thus far "

Shame we didn't get into bed with Gilead. They tested Remdes with every frikken drug on the planet including pile cream - but somehow it didn't happen with Synairgen. They could have funded outpatient AND inpatioent trials - as they are authorised in both spaces.
anyone else remember anything about this ?

Incidentally - saw a great twitter post today where someone described BBC News' funeral coverage as Mourn Hub.

thanks Prof - I was getting a bit worried there....

It's an interesting presentation Palladin. The company definitely in a rebranding process - or shifting back to its roots if you prefer and anticipating a post-Covid world. Hopefully this does not mean there isn't still a laser focus on proving the Sprinter promise. Whatever the long term promise of COPD or flu, Covid must still be the fastest route to authorisation.

oh go away - seriously - find someone else to pester with your nonsense.
What are you even doing here - defending your pal TommyD ? What business is it of yours, you pusillanimous fool ?
I'll have nothing further to say to you Mani - until you start the rampfest again

You were right about the trial start date of Univerdal Mani - well done